Advances in the sensitization mechanism of chemotherapeutic drugs for bladder cancer

doi:10.12092/j.issn.1009-2501.2019.09.015

Abstract

Abstract:

In recent years, chemoresistance has seriously restricted the therapeutic effect of bladder cancer, and the recurrence rate and metastasis rate remain high. Therefore, it is very important to reverse the resistance of bladder cancer to chemotherapy, and find more effective target of chemosensitizion and explore its mechanism. Transurethral resection of bladder tumors is commonly used in treatment of bladder cancer currently, and adjuvant chemotherapy drugs are utilized after operation. The most chemotherapy drugs used in bladder cancer include cisplatin, gemcitabine, adriamycin and epirubicin. At present, the target genes and molecules for enhancing chemosensitivity of these drugs display various expression states in bladder cancer cells, and the mechanisms for enhancing chemosensitivity through these targets are also different. In this paper, we will review the research progress of target and mechanism of chemosensitizing drugs for bladder cancer, and explore new ideas for chemosensitizion of bladder cancer.

Key words: bladder cancer, drug resistance, chemotherapy drugs, chemotherapy sensitization, target

CLC Number:

R737
R69

XU Weiping, ZHOU Weiying. Advances in the sensitization mechanism of chemotherapeutic drugs for bladder cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1060-1064.

References

［1］Rieger C, Huebner D, Temme A, et al. Antisense- and siRNA-mediated inhibition of the anti-apoptotic gene Bcl-xL for chemosensitization of bladder cancer cells［J］. Int J Oncol, 2015,47(3):1121-1130.
［2］Gan Y, He L, Yao K, et al. Knockdown of HMGN5 increases the chemosensitivity of human urothelial bladder cancer cells to cisplatin by targeting PI3K/Akt signaling［J］. Oncol Lett, 2017,14(6):6463-6470.
［3］Li CC, Yang JC, Lu MC, et al.ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer［J］. Oncotarget, 2016 ,7(2):1947-1959.
［4］Angell JE, Lindner DJ, Shapiro PS, et al. Identification of GRIM-19, a novel cell death-regulatory gene induced by the interferon-beta and retinoic acid combination, using a genetic approach［J］. J Biol Chem, 2000，275(43):33416-33426.
［5］Ni F, Yan CY, Zhou S, et al. Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation［J］. Cancer Chemother Pharmacol, 2018，82(4):593-605.
［6］Feng SQ, Zhang XY, Fan HT, et al. Up-regulation of LncRNA MEG3 inhibits cell migration and invasion and enhances cisplatin chemosensitivity of bladder cancer cells［J］. Neoplasma, 2018，65(6):925-932.
［7］Yan Z, Jiang J, Li F, et al. Adenovirus-mediated LRIG1 expression enhances the chemosensitivityof bladder cancer cells to cisplatin［J］. Oncol Rep, 2015，33(4):1791-1798.
［8］Chen J, Wang L, Tang Y, et al.Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscle-invasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy［J］. J Exp Clin Cancer Res, 2016，35:2.
［9］Zhou J, Dai W, Song J. miR-1182 inhibits growth and mediates the chemosensitivity of bladder cancer by targeting hTERT［J］. Biochem Biophys Res Commun, 2016，470(2):445-452.
［10］Zhang X, Zhang Y, Liu X, et al. MicroRNA-203 Is a prognostic indicator in bladder cancer and enhances chemosensitivity to cisplatin via apoptosis by targeting Bcl-w and Survivin［J］. PLoS One, 2015，10(11):e0143441.
［11］Lei Y, Li B, Tong S, et al. MiR-101 suppresses vascular endothelial growth factor C that inhibits migration and invasion and enhances cisplatin chemosensitivity of bladder cancer cells［J］. PLoS One, 2015，10(2):e0117809.
［12］Vinall RL, Ripoll AZ, Wang S, et al. MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status［J］. Int J Cancer, 2012，130(11):2526-2538.
［13］Lei Y, Hu X, Li B, et al. MiR-150 modulates cisplatin chemosensitivity and invasiveness of muscle-invasive bladder cancer cells via targeting PDCD4 in vitro［J］. Med Sci Monit, 2014，20:1850-1857.
［14］Cozzi PJ, Bajorin DF, Tong W, et al.Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs［J］. Clin Cancer Res, 1999，5(9):2629-2637.
［15］Behnsawy HM, Miyake H, Kusuda Y, et al. Small interfering RNA targeting heat shock protein 70 enhances chemosensitivity in human bladder cancer cells ［J］. Urol Oncol, 2013，31(6):843-848.
［16］Muramaki m, So A, Hayashi N, et al. Chemosensitization of gemcitabine-resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the anti-apoptotic gene, clusterin ［J］. BJU Int, 2009 ，103(3):384-390.
［17］Kraemer K, Fuessel S, Meye A. Telomerase inhibition by synthetic nucleic acids and chemosensitization in human bladder cancer cell lines［J］. Methods Mol Biol, 2007，405:9-22.
［18］Fuessel S, Herrmann J, Ning S, et al. Chemosensitization of bladder cancer cells by survivin-directed antisense oligodeoxynucleotides and siRNA［J］. CancerLett, 2006，232(2):243-254.
［19］Nordentoft I, Dyrskj TL, Bdker JS, et al. Increased expression of transcription factor TFAP2α correlates with chemosensitivity in advanced bladdercancer［J］. BMC Cancer, 2011，11:135.
［20］Brummelkamp TR, Nijman SM, Dirac AM, et al. Loss of cylindromatosis tumour suppressor inhibits apoptosis by activating NF-B［J］. Nature, 2003 ，424(6950):797-801.
［21］Alameda JP, Fernandez-acenero MJ, Moreno-maldonado R, et al. CYLD regulates keratinocyte, differentiation and skin cancer progression in humans［J］. Cell Death Dis, 2011, 2: e208.
［22］Kuphal S, Shaw-hallgren G, Eberl M, et al. GLI1-dependent transcriptional repression of CYLD in basal cell carcinoma［J］. Oncogene, 2011, 30(44): 4523-4530.
［23］Yin L, Liu S, Li C, et al. CYLD downregulates Livin and synergistically improves gemcitabinechemosensitivity and decreases migratory/invasive potential in bladdercancer: the effect is autophagy-associated［J］. Tumour Biol, 2016，37(9):12731-12742.
［24］Chen JF, Yu BX, Yu R, et al. Monoclonal antibody Zt/g4 targeting RON receptor tyrosine kinase enhances chemosensitivity of bladder cancer cells to epirubicin by promoting G1/S arrest and apoptosis［J］. Oncol Rep, 2017，37(2):721-728.
［25］Hu H, Han HY, Wang YL, et al. The role of Id-1 in chemosensitivity and epirubicin-induced apoptosis in bladder cancer cells［J］. Oncol Rep, 2009 ，21(4):1053-1059.
［26］Lu J, Luo JH, Pang J, et al. Lentivirus-mediated RNA interference of clusterin enhances the chemosensitivity of EJ bladdercancer cells to epirubicin in vitro［J］. Mol Med Rep, 2012，6(5):1133-1139.
［27］Romanova TV, Kotova SA, Amerik AIu，et al.ATP dependent protease La (lon) from escherichia coli［J］. Bioorg Khim，1994，20(2):114-125.
［28］Ondrovicova G, Liu T, Singh K, et al. Cleavage site selection within a folded substrate by the ATP dependent lon protease［J］. J Biol Chem, 2005， 280(26): 25103-25110.
［29］Liu Y, Lan L, Huang K, et al. Inhibition of Lon blocks cell proliferation, enhances chemosensitivity by promoting apoptosis and decreases cellular bioenergetics of bladdercancer: potential roles of Lon as a prognostic marker and therapeutic target in baldder cancer［J］. Oncotarget, 2014，5(22):11209-11224.
［30］Smolensky D, Rathore K, Cekanova M. Phosphatidylinositol-3-kinase inhibitor induces chemosensitivity to a novel derivative of doxorubicin, AD198 chemotherapy in human bladder cancer cells in vitro［J］. BMC Cancer, 2015，15:927.
［31］Kanai K, Kikuchi E, MIkami S, et al. Vitamin E succinate induced apoptosis and enhanced chemosensitivity to paclitaxel in humanbladder cancer cells in vitro and in vivo［J］. Cancer Sci, 2010，101(1):216-223.
［32］Zhang HH, Huang B, Cao YH, et al. Role of 5-Aza-CdR in mitomycin-C chemosensitivity of T24 bladder cancer cells［J］. Oncol Lett, 2017，14(5):5652-5656.

[1]	ZHANG Huyunlong, ZHU Xiuzhi, JIN Xi, SHAO Zhimin. Mechanisms of endocrine-resistance and therapeutic breakthroughs in hormone receptor-positive, HER2-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 854-865.
[2]	LUO Shiping, ZHANG Jie, YU Yushuai, SONG Chuangui. Advances in targeted therapy for HER2-positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 876-886.
[3]	XIANG Yimei, ZHANG Ningning, HUANG Yuxin, ZENG Xiaohua. Research progress of biomarkers related to the efficacy of HER2 positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 887-897.
[4]	WANG Anjing, WANG Yaya, LIANG Xuan, YAN Yajie, SU Jing, LI Caidong. Research progress on mechanisms and therapeutic drugs of peroxisome proliferator-activated receptor in treatment of cholestatic liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 796-808.
[5]	CHEN Manxin, ZHANG Bingyu, DAI Min. Clinical efficacy of intracoronally targeted recombinant human urokinase combined with percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI) with high thrombus burden [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 544-549.
[6]	FENG Zhuangzhuang, SONG Ruiping, DOU Pengcheng, CHEN Xinyi, ZUO Jiaojiao, SHU Jin. Effect of Zhiwei Fuwei Pills on autophagy in gastric antrum tissue of rats with precancerous lesions of gastric cancer based on mTOR/Beclin1/LC3 signaling axis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 361-370.
[7]	NING Sisi, ZHAO Yuhong, YAN Lei, TANG Minna, ZHANG Ningzhi, ZHANG Yongqiao, CUI Zhaoqiang. Controversies over the targets of controlling blood pressure in hyper- tensive patients with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 463-467.
[8]	LI Shan, LIU Yixin, REN Feifei, LI Xiangchen, ZHANG Zhiqing. Research progress of natural plant active ingredients in reversing tumor multidrug resistance by down-regulating P-gp [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 331-340.
[9]	ZHANG Wei, WANG Hongyuan, LEI Xiaohang, ZHAO Yingshuai, LV Weichao, ZHANG Jianguo. BCG + piroxicam versus BCG + gemcitabine for prevention of postoperative recurrence in intermediate- and high-risk bladder cancer and effects on serum AGR and PON1 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1146-1153.
[10]	LIU Jiajia, GAO Yan, ZHANG Yehui, WU Jing. Functions of CRABP2 in tumorigenesis and progression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 86-92.
[11]	WANG Lin, LI Chongyang, LI Shuaihu, GAO Shenghan, XU Tian, LI Fei. Research progress on pathogenic fusion gene in lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 877-885.
[12]	YE Xiaodi, MIAO Yunping, CHEN Aiying, CHENG Min, TIAN Xuejun, ZHENG Gaoli . Optimization and verification of orthotopic non-muscle invasive bladder cancer model in nude mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 473-480.
[13]	DONG Wei, HUANG Xiaoying, XIE Bingbin, TANG Xilan, LI Hongming, QIU Yumei, ZHAO Guowei, LIANG Xinli. Effects of oxypeucedanin on the resistance of breast cancer MCF-7/DOX cells to doxorubicin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 260-266.
[14]	DUAN Ruixiao, ZHAO Yifan, YE Yongjuan, LIU Min, LI Qiang, ZHOU Yongning. Mechanism of action of bile acid metabolism in regulating inflammatory bowel disease and the research and development of drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1171-1181.
[15]	CHEN Yunjie, ZHOU Xuan, ZHANG Yuanbin, WANG Xu, LIN Zhu, ZHU Suyan. Reseach progress on the role of ErbB2 in cardiac disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1182-1189.